KemPharm (NSDQ:KMPH) said yesterday it inked a collaborative licensing deal with KVK Tech to obtain U.S. commercial rights to the company’s FDA-approved Apadaz drug. Through the agreement, KemPharm is eligible to receive approximately $3.4 million in pre-launch payments and core cost reimbursement, including a $2 million milestone payment “related to the initial formulary adoption of Apadaz. […]
kempharm
KemPharm inks drug discovery deal with AI-driven biopharma
KemPharm (NSDQ:KMPH) said today that it inked a collaboration with twoXar to develop prodrug-based therapies for an array of therapeutic indications. According to the deal, twoXar’s artificial intelligence-based drug discovery technology will be used alongside KemPharm’s Ligand Activated Therapy platform to identify and develop new prodrug therapies. In conjunction with its deal with twoXar, KemPharm also inked a research and […]
KemPharm touts efficacy data for pediatric ADHD therapy
KemPharm (NSDQ:KMPH) touted top-line data from a pivotal efficacy and safety trial of its KP415 pediatric ADHD product. The company reported that KP415, which consists of serdexmethylphenidate and d-methylphenidate, met the primary efficacy endpoint in people with attention-deficit/hyperactivity disorder between the ages of 6 and 12 years. KemPharm’s KP415 capsule makes use of d-MPH hydrochloride as […]
KemPharm wins FDA nod for short-term pain prodrug
Shares in KemPharm (NSDQ:KMPH) soared today after the company said that the FDA approved a re-submitted application for its pain-relief prodrug, Apadaz. The product, which combines benzhydrocodone and acetaminophen, is indicated for the short-term management of acute pain. The FDA rejected KemPharm’s first attempt at regulatory approval for Apadaz in 2016. Today’s win for KemPharm is […]
KemPharm launches pivotal efficacy trial for extended-release ADHD prodrug
KemPharm (NSDQ:KMPH) has launched a pivotal efficacy trial of its extended-release prodrug product for the treatment of attention deficit hyperactivity disorder in children. The company’s classroom-style study is designed to support a potential label for KP415 that would include both early-onset and long duration treatment effect for ADHD. The 140-patient trial is slated to wrap up […]
KemPharm partners to develop therapy for kids with Tourette’s syndrome and ADHD
KemPharm (NSDQ:KMPH) said yesterday that it inked a technology licensing and assignment deal with Genco Sciences to develop a treatment for kids with Tourette’s syndrome and ADHD. Genco has won orphan designation from the FDA for its pediatric Tourette’s syndrome product candidate. KemPharm said it plans to use Genco’s nanoparticulate amphetamine technology to develop a prodrug […]
KemPharm tackles pediatric ADHD using ligand-activated drug
Travis Mickle’s work developing better drugs for attention deficit hyperactivity disorder is deeply personal – he has ADHD and so do his children. After receiving his PhD in organic chemistry from the University of Iowa, Mickle went on to work at New River Pharmaceuticals, where he developed the leading treatment for ADHD, Vyvanse. Now he […]
